Skip to main content
ANTEROGEN CO., LTD. logo

ANTEROGEN CO., LTD. — Investor Relations & Filings

Ticker · 065660 ISIN · KR7065660003 KO Manufacturing
Open in API
Filings indexed 267 across all filing types
Latest filing 2025-02-20 AGM Information
Country KR South Korea
Listing KO 065660

About ANTEROGEN CO., LTD.

http://anterogen.com

ANTEROGEN CO., LTD. is a bio-venture company engaged in the research, development, and commercialization of cell therapy products and orphan drugs. The company specializes in utilizing adult stem cells, particularly adipose-derived mesenchymal stem cells, to create innovative treatments. Its key commercialized products include Cupistem®, an autologous stem cell therapy for Crohn's fistula, and Queencell®. Anterogen's research pipeline extends to applications for musculoskeletal diseases, spinal injuries, and cardiovascular conditions. The company also offers stem cell banking services.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company (Antrogen) is holding its meeting on a date designated as a 'concentrated date' by the KOSDAQ Association. This is a standard regulatory disclosure required for corporate governance compliance and does not fit into specific categories like AGM-R (presentation materials) or PSI (proxy solicitation). Therefore, it is classified as a general regulatory filing.
2025-02-20 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) filed by Anterogen. It details the amendment of the listing date for new shares and provides specific information on the third-party allocation of shares, including the purpose of funds and the list of investors. This falls under the category of announcements regarding new share issues and capital changes.
2025-02-10 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by Antrogen. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2025-01-31 Korean
투자판단관련주요경영사항(임상시험결과) (Wagner grade 1 당뇨병성 족부궤양 환자를 대상으로 한 ALLO-ASC-SHEET 미국 임상 2상 Topline data수령)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from a Korean company (Antrogen) regarding the results of a Phase 2 clinical trial. It details the trial methodology, primary endpoints, and the specific outcome (top-line data) of the study. Since it is a direct announcement of material business information regarding clinical trial results rather than a full report or a simple publication notice, it falls under the 'Regulatory Filings' category as a standard corporate disclosure.
2025-01-31 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission and the Korea Exchange. It specifically details a 'Decision on Paid-in Capital Increase' (유상증자결정), which involves the issuance of new shares via third-party allocation. This falls under the category of capital structure changes and financing activities. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the correct classification for announcements regarding new share issues and capital changes.
2025-01-23 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notification of the administrative process required for the meeting. Given it is a regulatory announcement regarding corporate governance procedures, it fits best under the RNS category.
2024-12-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.